TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07613424: A Multicenter, Prospective Study of MET Concordance and Gene Profiling in First-line Non-small Cell Lung Cancer (NSCLC) (Genomet)

Sponsor: AstraZeneca · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 1000 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,484,400

Rescue Site Savings

+$4,943,400

Unlock Full NCT07613424 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07613424 Rescue Dossier →